Exponential Learning

Abbott Q3 2026: A Choppy Quarter, a Slower Libre, and a Nutrition Spin-Off

17:00

Abbott's Q3 2026 was in line on the numbers — sales of $13.0B, comparable growth of 7.0%, adjusted EPS of $1.42 — but the stock fell as management cut full-year comparable sales growth guidance to ~6% and guided diabetes care to low-to-mid single-digit growth for the next few quarters. Electrophysiology (+15%) and the Exact Sciences cancer diagnostics business (+14%) are carrying growth while…